Family matters: How MYC family oncogenes impact small cell lung cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cell Cycle

• Publication date

  2017-07-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/15384101.2017.1339849PMID 28737478PMCID PMC5584863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

  2017influential reference
• Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

  2017cited by this paper
• Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

  2017cited by this paper
• CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

  2017cited by this paper
• Different promoter affinities account for specificity in MYC-dependent gene regulation

  2016cited by this paper
• Author response: Different promoter affinities account for specificity in MYC-dependent gene regulation

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

  2016cited by this paper
• Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

  2016cited by this paper
• Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients

  2016cited by this paper
• Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.

  2016cited by this paper
• Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

  2016cited by this paper
• N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

  2016cited by this paper
• Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

  2016cited by this paper
• ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

  2016cited by this paper
• MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells

  2016cited by this paper
• Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

  2016cited by this paper
• Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo

  2016cited by this paper
• Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

  2016cited by this paper
• Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma.

  2016cited by this paper
• A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer

  2016cited by this paper
• The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.

  2016cited by this paper
• Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.

  2015cited by this paper
• BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

  2015cited by this paper
• Small-molecule inhibitors of the Myc oncoprotein.

  2015cited by this paper
• Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression

  2015cited by this paper
• MYC Is a Major Determinant of Mitotic Cell Fate

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Comprehensive genomic profiles of small cell lung cancer

  2015cited by this paper
• Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

  2015cited by this paper
• Repression of SRF target genes is critical for Myc‐dependent apoptosis of epithelial cells

  2015cited by this paper
• The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung

  2015cited by this paper
• Multiple mechanisms of MYCN dysregulation in Wilms tumour

  2015cited by this paper
• Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

  2015cited by this paper
• Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

  2015cited by this paper
• The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

  2015cited by this paper
• DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

  2015cited by this paper
• CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

  2014cited by this paper
• Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

  2014cited by this paper
• Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

  2014cited by this paper
• Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

  2014cited by this paper
• MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma

  2014cited by this paper
• Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

  2014influential reference
• A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy.

  2014cited by this paper
• Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells

  2014cited by this paper
• Drugging MYCN through an allosteric transition in Aurora kinase A.

  2014cited by this paper
• BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.

  2014cited by this paper
• ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

  2014cited by this paper
• Sequence specificity incompletely defines the genome-wide occupancy of Myc

  2014cited by this paper
• MicroRNA-130a associates with ribosomal protein L11 to suppress c-Myc expression in response to UV irradiation

  2014cited by this paper
• CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

  2014cited by this paper
• CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

  2014cited by this paper
• PTEN Is a Potent Suppressor of Small Cell Lung Cancer

  2014cited by this paper
• Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.

  2014cited by this paper
• Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers

  2013cited by this paper
• Cdc45 is a critical effector of myc-dependent DNA replication stress.

  2013cited by this paper
• BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

  2013cited by this paper
• Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.

  2013cited by this paper
• Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

  2013cited by this paper
• Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

  2013cited by this paper
• Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

  2013cited by this paper
• MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells

  2013cited by this paper
• Transcriptional amplification in tumor cells with elevated c-Myc.

  2012cited by this paper
• A framework for identification of actionable cancer genome dependencies in small cell lung cancer

  2012cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

  2012cited by this paper
• c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

  2012cited by this paper
• New model systems provide insights into Myc-induced transformation

  2011cited by this paper
• A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.

  2011cited by this paper
• Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation

  2011cited by this paper
• Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression

  2011cited by this paper
• Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts

  2011cited by this paper
• Ribosomal Protein L11 Recruits miR-24/miRISC To Repress c-Myc Expression in Response to Ribosomal Stress

  2011cited by this paper
• Expression of NLRR3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma

  2011cited by this paper
• Nuclear factor I/B is an oncogene in small cell lung cancer.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Pleiotropic role for MYCN in medulloblastoma.

  2010cited by this paper
• Cellular nucleic-acid-binding protein, a transcriptional enhancer of c-Myc, promotes the formation of parallel G-quadruplexes.

  2010cited by this paper
• c-Myc regulates transcriptional pause release.

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization

  2010cited by this paper
• Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

  2010cited by this paper
• Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR.

  2010cited by this paper
• Neuroendocrine tumors of the lung: an update.

  2010cited by this paper
• Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

  2009cited by this paper
• c-Myc-induced Aberrant DNA Synthesis and Activation of DNA Damage Response in p300 Knockdown Cells*

  2009cited by this paper
• Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc.

  2009cited by this paper
• Lung tumours with neuroendocrine differentiation.

  2009cited by this paper
• Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene

  2009cited by this paper
• A β-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers

  2009cited by this paper
• Modelling Myc inhibition as a cancer therapy

  2008cited by this paper
• Distinct thresholds govern Myc's biological output in vivo.

  2008cited by this paper
• Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs.

  2008cited by this paper
• Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC

  2007cited by this paper
• P-TEFb is a Crucial Co-Factor for Myc Transactivation

  2007cited by this paper
• Non-transcriptional control of DNA replication by c-Myc

  2007cited by this paper
• c-MYC Delays Prometaphase by Direct Transactivation of MAD2 and BubR1: Identification of Mechanisms Underlying c-MYC-Induced DNA Damage and Chromosomal Instability

  2007cited by this paper
• Global mapping of c-Myc binding sites and target gene networks in human B cells

  2006cited by this paper

• Intratumoral heterogeneity and potential treatment strategies in small cell lung cancer

  2025cites this paper
• Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription

  2025cites this paper
• Carrageenan grafted with acrylic acid and sulfonamide induces apoptosis and suppresses proliferation in A549 lung cancer cells: synthesis, cytotoxicity, gene expression, and in silico studies

  2025cites this paper
• Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer.

  2025cites this paper
• WIPF1 regulates stemness in small cell lung cancer

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  2024cites this paper
• Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer

  2024cites this paper
• Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer

  2024cites this paper
• Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15

  2024cites this paper
• Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel

  2024cites this paper
• Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer.

  2024cites this paper
• Personalized treatment using predictive biomarkers in solid organ malignancies: A review

  2024cites this paper
• Applied models and molecular characteristics of small cell lung cancer

  2024cites this paper
• Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

  2024cites this paper
• C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer

  2024cites this paper
• Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.

  2024cites this paper
• Genetic Alterations in Lung Cancer

  2024cites this paper
• PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities.

  2023cites this paper
• Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.

  2023cites this paper
• DNA-PKcs as an upstream mediator of OCT4-induced MYC activation in small cell lung cancer.

  2023cites this paper
• Demystifying the Druggability of the MYC Family of Oncogenes.

  2023cites this paper
• The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.

  2023cites this paper
• The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC

  2022influential citation
• Signal pathways and precision therapy of small-cell lung cancer

  2022cites this paper
• c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation

  2022cites this paper
• KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma

  2022cites this paper
• Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells

  2022cites this paper
• Killing SCLC: insights into how to target a shapeshifting tumor

  2022cites this paper
• Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts

  2022cites this paper
• RNA Sequencing of Tumor-Educated Platelets Reveals a Three-Gene Diagnostic Signature in Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Genetic Alteration and Their Significance on Clinical Events in Small Cell Lung Cancer

  2022cites this paper
• Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study

  2022influential citation
• Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers

  2022cites this paper
• Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.

  2022cites this paper
• MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype

  2021cites this paper
• Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer

  2021cites this paper
• Cancer Hallmarks Define a Continuum of Plastic Cell States between Small Cell Lung Cancer Archetypes

  2021cites this paper
• MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma

  2021cites this paper
• Stem cells and lung cancer

  2021cites this paper
• Effect of LINC00320 Regulating the Expression of PLEKHA1 through the Transcription Factor MYC in Glioma Cell Proliferation, Migration, Invasion and Apoptosis In vivo and In vitro

  2021cites this paper
• ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer

  2021cites this paper
• MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma

  2021cites this paper
• Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.

  2021cites this paper
• Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

  2021cites this paper
• Down-Regulation of CXXC5 De-Represses MYCL1 to Promote Hepatic Stellate Cell Activation

  2021cites this paper
• Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease

  2021influential citation
• Role of Rho guanine nucleotide exchange factors in non-small cell lung cancer

  2021cites this paper
• Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?

  2021cites this paper
• RHO Guanine Nucleotide Exchange Factors Predict Prognosis of Non-Small Cell Lung Cancer: A Comprehensive Bioinformatics Analysis

  2020cites this paper
• BCAT1 Overexpression Promotes Proliferation, Invasion, and Wnt Signaling in Non-Small Cell Lung Cancers

  2020cites this paper
• A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

  2020cites this paper
• New insights into small‐cell lung cancer development and therapy

  2020cites this paper
• New Approaches to SCLC Therapy: From the Laboratory to the Clinic

  2020cites this paper
• Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status

  2020cites this paper
• Pre-clinical models of small cell lung cancer and the validation of therapeutic targets

  2020cites this paper
• New approaches to small cell lung cancer therapy : from the laboratory to the clinic.

  2020cites this paper
• C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target

  2020cites this paper
• MYC, MYCL, and MYCN as therapeutic targets in lung cancer

  2020cites this paper
• Targeting MYC Proteins for Tumor Therapy

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• HTLV-1 Tax Stimulates Molecular Events in Various Cancers

  2020cites this paper
• Histone methyltransferase SETD1A participates in lung cancer progression

  2020cites this paper
• Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers

  2020cites this paper
• OTT_A_237306 3583..3594

  2020cites this paper
• Epigenetic Landscape of Small Cell Lung Cancer: Small Image of a Giant Recalcitrant Disease.

  2020cites this paper
• ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin

  2020cites this paper
• The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• llncRNAs as Potential Targets in Small Cell Lung Cancer: Myc Dependent Regulation.

  2020cites this paper
• Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets

  2020cites this paper
• A Comprehensive Network Pharmacology-Based Strategy to Investigate Multiple Mechanisms of HeChan Tablet on Lung Cancer

  2020cites this paper
• High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms

  2020cites this paper
• Novel c-Myc–Targeting Compound N, N-Bis (5-Ethyl-2-Hydroxybenzyl) Methylamine for Mediated c-Myc Ubiquitin-Proteasomal Degradation in Lung Cancer Cells

  2020cites this paper
• MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.

  2020cites this paper
• βKlotho is identified as a target for theranostics in non-small cell lung cancer

  2019cites this paper
• Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins

  2019cites this paper
• LncRNA EPIC1 downregulation mediates hydrogen peroxide-induced neuronal cell injury

  2019cites this paper
• Classic oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer

  2019cites this paper
• Long non-coding RNA EPIC1 promotes human lung cancer cell growth.

  2018cites this paper
• Whole-Genome Resequencing of Red Junglefowl and Indigenous Village Chicken Reveal New Insights on the Genome Dynamics of the Species

  2018cites this paper
• Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth.

  2018cites this paper
• Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

  2018cites this paper
• The Synergistic Effects Study of C-myc and C-erbB-2 in the Carcinogenesis of Gastric Carcinoma

  2017cites this paper
• Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers

  year unknowncites this paper